Ovid Therapeutics to Participate in Upcoming Investor Conferences

About this update from Ovid Therapeutics Inc.

NEW YORK , Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the Company’s management will participate in three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference – Wednesday, February 25th at 11:20 am ET 46th Annual TD Cowen Health Care Conference – Wednesday, March 4 th at 9:50 am ET Leerink Partners Global Healthcare Conference 2026 – Wednesday, March 11th at 3:00 pm ET A live webcast of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com . An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York -based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions and symptoms caused by excess neural excitability. Ovid is advancing a pipeline of novel targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; and is developing OV4071 and other candidates within a library of compounds that directly activate the KCC2 transporter for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com . Contact Investor Relations & Media Victoria Fort [email protected] 202.361.0445 Source: Ovid Therapeutics Inc.

View stock analysis, news, and events for Ovid Therapeutics Inc.